Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion
Robert Driscoll

Robert Driscoll Analyst Performance

Senior Vice President, Equity Research at Wedbush

Robert Driscoll is a stock analyst at Wedbush in the healthcare sector, covering 28 publicly traded companies. Over the past year, Robert Driscoll has issued 71 stock ratings, including buy, hold, and sell recommendations. While full access to Robert Driscoll's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Robert Driscoll's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
91 Last 8 Years
Buy Recommendations
78.89% 71 Buy Ratings
Companies Covered
28 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy78.9%71 ratings
Hold15.6%14 ratings
Sell5.6%5 ratings

Out of 90 total stock ratings issued by Robert Driscoll at Wedbush, the majority (78.9%) have been Buy recommendations, followed by 15.6% Hold and 5.6% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
96.4% of companies on NASDAQ
27 companies
NYSE
3.6% of companies on NYSE
1 company

Robert Driscoll, an analyst at Wedbush, currently covers 28 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
28 companies
100.0%

Robert Driscoll of Wedbush specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
27 companies
96.4%
PHARMACEUTICALS
1 company
3.6%

About Robert Driscoll

Robert Driscoll, Ph.D., has over a decade in research and analytics in the life sciences sector – specifically in the area of oncology and more recently in the areas of infectious disease. He is a molecular biologist who received his Ph.D. from the University of Cambridge, and spent six additional years working in the lab at Stanford. He is particularly interested in the development and causes of cancer, as well as the expanding world of immuno-oncology. Since joining Wedbush in 2014, Robert has been covering a number of cutting-edge companies that include Arvinas (ARVN), Kura Oncology (KURA), Arcus Biosciences (RCUS), and IGM Biosciences (IGMS). Robert received his Bachelor’s degree in Biochemistry from the University of Leeds, and his Ph.D. in Cellular and Molecular Biology from the University of Cambridge. He also completed a postdoctoral fellowship at Stanford University.
Follow on LinkedIn

Robert Driscoll's Ratings History at Wedbush

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
10/23/2026Lower Price Target$7.45$22.00Outperform
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
10/21/2026Boost Price Target$23.69$49.00Outperform
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
10/2/2026Downgrade$2.92$2.00Neutral
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
9/30/2026Reiterated Rating$25.67$43.00Outperform
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
9/28/2026Reiterated Rating$6.52$28.00Outperform
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
9/23/2026Set Price Target$1.24$4.00
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
9/22/2026Downgrade$1.24$1.00Neutral
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
9/14/2026Reiterated Rating$19.41$27.00Outperform
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
9/10/2026Boost Price Target$3.38$8.00Outperform
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
9/10/2026Reiterated Rating$22.01$53.00Outperform
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
9/9/2026Reiterated Rating$14.27$27.00Outperform
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
8/27/2026Boost Price Target$219.02$225.00Outperform
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
8/27/2026Reiterated Rating$17.80$27.00Outperform
EIKN
Eikon Therapeutics
8/14/2026Lower Price Target$9.86$4.00Underperform
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
8/13/2026Boost Price Target$19.60$42.00Outperform
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
8/13/2026Boost Price Target$9.94$38.00Outperform
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
8/13/2026Lower Price Target$0.68$3.00Outperform
Replimune Group, Inc. stock logo
REPL
Replimune Group
8/7/2026Upgrade$12.86$12.00Outperform
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
8/6/2026Boost Price Target$198.97$201.00Outperform
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
8/6/2026Boost Price Target$27.92$43.00Outperform
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
8/5/2026Boost Price Target$36.11$60.00Outperform
Arvinas, Inc. stock logo
ARVN
Arvinas
8/5/2026Boost Price Target$9.00$12.00Neutral
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
8/3/2026Lower Price Target$16.57$27.00Outperform
Replimune Group, Inc. stock logo
REPL
Replimune Group
7/31/2026Upgrade$5.50$12.00Outperform
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
7/28/2026Reiterated Rating$10.15$36.00Outperform
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
7/23/2026Boost Price Target$190.09$192.10Outperform
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
7/2/2026Boost Price Target$185.36$181.00Outperform
Replimune Group, Inc. stock logo
REPL
Replimune Group
6/30/2026Boost Price Target$11.20$9.00Neutral
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
6/12/2026Reiterated Rating$29.45$58.00Outperform
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
6/11/2026Reiterated Rating$12.11$37.00Outperform
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
6/2/2026Reiterated Rating$28.94$58.00Outperform
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
6/1/2026Reiterated Rating$163.40Outperform
Replimune Group, Inc. stock logo
REPL
Replimune Group
6/1/2026Boost Price Target$9.19$6.00Neutral
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
5/27/2026Lower Price Target$7.91$30.00Outperform
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
5/14/2026Lower Price Target$19.85$34.00Outperform
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
5/14/2026Boost Price Target$23.72$33.00Outperform
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
5/14/2026Lower Price Target$0.90$6.00Outperform
EIKN
Eikon Therapeutics
5/12/2026Lower Price Target$9.95$5.00Underperform
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
5/8/2026Boost Price Target$14.96$37.00Outperform
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
5/8/2026Lower Price Target$14.30$36.00Outperform
Why Gerardo Del Real says wait before buying uranium stocks (Ad)

Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he says has never existed before. In a similar setup in the past, select investors saw $1,000 turn into over $1 million within a few years. Del Real just released a full video breakdown of what is driving this move and how to prepare.tc pixel

Watch Gerardo Del Real's new uranium market breakdown now
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
5/7/2026Boost Price Target$144.46$165.00Outperform
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
5/6/2026Boost Price Target$16.26$40.00Outperform
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
5/5/2026Initiated Coverage$1.76$6.00Outperform
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
4/14/2026Boost Price Target$30.82$58.00Outperform
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
4/14/2026Reiterated Rating$138.88Outperform
Replimune Group, Inc. stock logo
REPL
Replimune Group
4/13/2026Reiterated Rating$4.77$2.00Neutral
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
4/2/2026Boost Price Target$21.89$41.00Outperform
EIKN
Eikon Therapeutics
3/31/2026Reiterated Rating$10.03$7.00Underperform
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
3/31/2026Reiterated Rating$33.36$52.00Outperform
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
3/31/2026Reiterated Rating$0.74$7.00Outperform
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
3/17/2026Boost Price Target$2.19$14.00Outperform
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
3/17/2026Boost Price Target$6.75$11.00Outperform
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
3/12/2026Reiterated Rating$4.87$10.00Outperform
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
3/11/2026Boost Price Target$14.91$36.00Outperform
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
3/9/2026Reiterated Rating$21.20$21.50Neutral
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
3/6/2026Lower Price Target$8.51$36.00Outperform
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
3/6/2026Boost Price Target$16.80$19.00Outperform
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
3/6/2026Downgrade$21.20Hold
EIKN
Eikon Therapeutics
2/26/2026Initiated Coverage$14.89$7.00Underperform
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
2/25/2026Boost Price Target$12.02$30.00Outperform
Arvinas, Inc. stock logo
ARVN
Arvinas
2/24/2026Boost Price Target$11.99$11.00Neutral
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
2/18/2026Boost Price Target$30.76$52.00Outperform
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
2/13/2026Boost Price Target$29.60$53.00Outperform
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
2/10/2026Lower Price Target$0.64$7.00Outperform
Replimune Group, Inc. stock logo
REPL
Replimune Group
2/4/2026Boost Price Target$7.35$19.00Outperform
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
1/9/2026Reiterated Rating$107.39$147.00Outperform
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
12/16/2025Boost Price Target$22.12$37.00Outperform
CG Oncology, Inc. stock logo
CGON
CG Oncology
12/11/2025Initiated Coverage$41.74$70.00Outperform
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
12/9/2025Boost Price Target$12.44$34.00Outperform
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
11/14/2025Reiterated Rating$10.68$38.00Outperform
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
11/6/2025Boost Price Target$59.34$80.00Outperform
Replimune Group, Inc. stock logo
REPL
Replimune Group
10/20/2025Upgrade$4.50$18.00Outperform
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
10/20/2025Boost Price Target$19.32$38.00Outperform
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
10/17/2025Reiterated Rating$49.68$77.00Outperform
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
9/11/2025Boost Price Target$40.45$77.00Outperform
Replimune Group, Inc. stock logo
REPL
Replimune Group
7/22/2025Reiterated Rating$3.14$4.00Neutral
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
7/14/2025Initiated Coverage$12.96$27.00Outperform
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
6/20/2025Reiterated Rating$6.06$36.00Outperform
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
5/15/2025Reiterated Rating$1.18$4.00Neutral
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
5/9/2025Lower Price Target$0.82$6.00Outperform
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
4/28/2025Reiterated Rating$41.02$67.00Outperform
Zentalis Pharmaceuticals, Inc. stock logo
ZNTL
Zentalis Pharmaceuticals
3/28/2025Reiterated Rating$1.70$4.00Neutral
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
3/20/2025Reiterated Rating$7.06$17.00Outperform
Arvinas, Inc. stock logo
ARVN
Arvinas
3/12/2025Downgrade$8.30$12.00Neutral
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
3/12/2025Reiterated Rating$1.30$8.00Outperform
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
2/26/2025Reiterated Rating$10.25$32.00Outperform
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
2/6/2025Boost Price Target$8.13$36.00Outperform